AI-based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report By Therapeutic Application, By Clinical Trial Phase, By End-use, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global AI-based Clinical Trials Solution Provider market size was valued at USD 2.3 billion in 2021 and is predicted to hit USD 8.7 billion by 2030 with a registered CAGR of 23.0% during the forecast period 2022 to 2030.

AI is a versatile tool and is being increasingly utilized to improve the operational efficacy of drug studies and accelerate the drug discovery process. Also, it is highly adopted to minimize the cost of the drug development process. Various academia and pharmaceutical companies are actively adopting AI-based platforms and technologies. For instance, in January 2020, Bayer entered into a partnership with an AI-driven drug discovery company based in the UK to work on early research projects using the AI drug discovery platform. Furthermore, the initiatives by the public and private sectors to boost the R&D coupled with the diverse applications provided by AI in the field of drug studies are impelling the growth. 

Based on the phase of the clinical trial, Phase II dominated the market with a share of 47.2% in 2021 owing to the rising number of drug discoveries and a large number of studies active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the clinical trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase. 

In 2021, based on therapeutic applications, oncology accounted for the highest revenue share in the AI-based clinical trials solution provider market. The increasing prevalence of cancer across the globe and the rising number of drug studies in the field of oncology is contributing to the adoption of AI enables technologies. Also, an increasing number of players are developing and adopting advanced oncology-based AI tools for drug studies, thereby propelling the segment growth. 

In 2021, pharmaceutical companies accounted for the highest revenue share in the market, based on end-use. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers, to identify the new drug target and the overall process of drug development and drug trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendor for leveraging the AI technology for R&D and the overall drug discovery process, thereby, impelling the growth. 

North America dominated the market and accounted for a revenue share of 43.8% in 2021. This dominance is attributed to the rising number of start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Also, the growing awareness of AI-based technologies and their adoption to enhance the drug studies’ outcomes is impelling the market growth in the region. Furthermore, the supportive government initiatives and increasing strategic initiatives by major players are driving the demand for AI-based clinical trial solutions in the region. 

The AI-based technologies witnessed a surge in their adoption due to the outbreak of COVID-19. This increasing adoption of technologically advanced solutions for drug development and for the analyses of the recruited patient’s data contributed to the upsurge in the adoption of AI-enabled solutions. Moreover, many drug development processes were on hold during the pandemic. Therefore, many key companies in the market shifted their focus on the utilization of AI-based solutions, thereby boosting decentralized drug trials. Furthermore, the effective analysis of a large amount of patient data through these solutions supported the market growth. 

Report Scope of the AI-based Clinical Trials Solution Provider Market

Report Coverage

Details

Market Size

USD 8.7 Billion by 2030

Growth Rate

CAGR of 23.0% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

 Clinical trial phase, therapeutic application, end-use and Region,

Companies Mentioned

 Unlearn.AI, Inc.; Saama Technologies; Antidote Technologies, Inc.; Phesi; Deep 6 AI; Innoplexus; Mendel.ai; Intelligencia; Median Technologies; Symphony AI; BioAge Labs, Inc.; AiCure, LLC; CONSILX; DEEP LENS AI; Halo Health Systems; Pharmaseal; Ardigen; Trials.Ai; Koneksa Health; Euretos; BioSymetrics; Google- Verily; GNS Healthcare; IBM Watson; Exscientia

Key Takeaways:

  • The market size is anticipated to be valued at USD 8.8 billion by 2030, owing to various applications provided by AI in the field of clinical trials and the growing adoption of such platforms by pharmaceutical companies
  • The phase-II trials segment dominated the market in 2021, owing to the increasing number of active drug studies in this phase
  • The oncology segment dominated the market in 2021, owing to the rising prevalence of cancer and the growing number of drug studies in the oncology field
  • The pharmaceutical companies segment accounted for the highest revenue share in the market owing to the increasing adoption of artificial intelligence technologies for drug development by major pharmaceutical players
  • North America dominated the market and accounted for a revenue share of 44.8% in 2021, owing to various factors including the increasing number of clinical trials in the region, growing adoption of artificial intelligence platforms and tools, rising number of start-ups and companies based on artificial intelligence in drug development and growing awareness regarding AI-based tools and technologies

Clinical Trial Phase Insights

The phase-II segment dominated the market for AI-based clinical trial solution providers and accounted for a revenue share of 48.2% in 2021, owing to the presence of a large number of registered clinical trials active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the drug trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase. 

In addition, the phase-I segment is expected to witness the fastest growth during the forecast period. The adoption of AI-based solutions is anticipated to increase, as their utilization since phase I can be beneficial for patient recruitment, retention, and better trial design. Also, these platforms can develop unique patient-centric endpoints and collect real-world data, thereby impelling the adoption of these solutions in phase-I. 

Therapeutic Application Insights

The oncology segment accounted for the highest revenue share of 24.2% in 2021. The high prevalence of cancer across the globe and a large number of drug trials in the field of oncology is contributing to the adoption of AI-enabled technologies. Also, a large number of players are developing and adopting oncology-based AI tools for clinical trials, thereby propelling the segment growth. For instance, in January 2022, Hematology-Oncology Associates of Central New York and Deep Lens partnered for the expansion of a drug trial program, wherein The VIPER provided by Deep Lens will be used to identify the qualified patients for clinical trials by pre-screening all patients. 

In addition, the Cardiovascular Disease (CVD) segment is expected to witness the highest CAGR during the forecast period owing to the rising prevalence of CVD across the globe. Also, the improving drug trials and increasing penetration of AI-based platforms for the analysis of cardiovascular diseases with a new approach are major factors contributing to the segment growth. 

End-use Insights

In 2021, based on end-use, the pharmaceutical companies segment accounted for the highest revenue share of 67.0%. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers to identify the new drug target, and the overall process of drug development and clinical trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendors for leveraging the AI technology for R&D and the overall drug discovery process, thereby, impelling the growth. For instance, in April 2020, Vir Biotechnology and GSK signed an agreement to boost the drug discovery for COVID-19 by utilizing CRISPR and AI.

However, the others segment is expected to witness the highest CAGR during the forecast period owing to the rising trend of adoption of AI-enabled solutions by Contract Research Organizations, government agencies, etc. The rising participation of CROs and other organizations in the development and adoption of AI-based platforms and technologies, useful in drug discovery and development, along with clinical trials, is anticipated to boost the growth of the market for AI-based clinical trial solution providers during the forecast period. 

Regional Insights

North America dominated the global AI-based clinical trials solution providers market and accounted for a revenue share of 44.8% in 2021. It is attributed to the presence of a number of AI-based start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Furthermore, the growing awareness of AI-based technologies and their adoption to enhance the drug trial outcome is impelling market growth in the region. The supportive government initiatives and increasing strategic initiatives by major players are among a few factors that are driving the demand for AI-based clinical trial solutions in the region. 

However, in Asia Pacific, the market for AI-based clinical trial solution providers is expected to exhibit lucrative growth over the forecast period due to the rising penetration of AI-based tools and favorable government initiatives for the adoption of AI in different healthcare fields. Recruitment for clinical trials is increasing in Asia as compared to North America and Europe. This is due to the presence of a large patient pool and low trial cost. Furthermore, as per Novotech’s CEO, Asia Pacific is now recognized by clinical phase biotechnology firms for accelerated patient enrollment, especially in infectious diseases, oncology, metabolic conditions, immune-oncology, and rare diseases as well as low cost of clinical research combined with experienced investigators and research teams. 

Some of the prominent players in the AI-based Clinical Trials Solution Provider Market include:

  • Unlearn.AI, Inc.
  • Saama Technologies
  • Antidote Technologies, Inc.
  • Phesi
  • Deep 6 AI
  • Innoplexus
  • Mendel.ai
  • Intelligencia
  • Median Technologies
  • Symphony AI
  •  BioAge Labs, Inc.
  • AiCure, LLC
  • CONSILX
  • DEEP LENS AI
  • Halo Health Systems
  • Pharmaseal
  • Ardigen
  • Trials.Ai
  • Koneksa Health
  • Euretos
  • BioSymetrics
  • Google- Verily
  • GNS Healthcare
  • IBM Watson
  • Exscientia 

 Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global AI-based Clinical Trials Solution Provider market

  • Clinical Trial Phase
    • Phase-I
    • Phase-II
    • Phase-III
  • Therapeutic Application 
    • Oncology
    • Cardiovascular Diseases
    • Neurological Diseases or Conditions
    • Metabolic Diseases
    • Infectious Diseases
    • Others
  • End-user 
    • Pharmaceutical Companies
    • Academia
    • Others

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global AI-based Clinical Trials Solution Provider industry analysis from 2022 to 2030 to identify the prevailing AI-based Clinical Trials Solution Provider industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global AI-based Clinical Trials Solution Provider industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global AI-based Clinical Trials Solution Provider industry trends, key players, market segments, application areas, and market growth strategies.

Chapter 1 Research Methodology & Scope
                   1.1 Market Segmentation and Scope
                   1.2 Market Definition
                   1.3 Research Methodology
                       1.3.1 Information Procurement
                           1.3.1.1 Purchased database
                           1.3.1.2 Nova one advisor’s internal database
                       1.3.2 Primary Research
                   1.4 Research Scope and Assumptions
                   1.5 List of Data Sources
Chapter 2 Executive Summary
                   2.1 Market Outlook
                   2.2 Segment Outlook
Chapter 3 Global AI-based Clinical Trial Solution Providers Market Variables, Trends, & Scope
                   3.1 Penetration and Growth Prospect Mapping
                   3.2 Market Dynamics
                       3.2.1 Market Driver Analysis
                       3.2.2 Market Restraint Analysis
                   3.3 Global AI-based Clinical Trial Solution Providers Market Analysis Tools
                       3.3.1 Industry Analysis - Porter’s
                           3.3.1.1 Bargaining power of the suppliers
                           3.3.1.2 Bargaining power of the buyers
                           3.3.1.3 Threats of substitution
                           3.3.1.4 Threats from new entrants
                           3.3.1.5 Competitive rivalry
                       3.3.2 PESTEL Analysis
                           3.3.2.1 Political landscape
                           3.3.2.2 Economic and Social landscape
                           3.3.2.3 Technology landscape
                           3.3.2.4 Legal landscape
                           3.3.2.5 Technology landscape
                       3.3.3 Major Deals & Strategic Alliances Analysis
                   3.4 COVID-19 Impact on the market
Chapter 4 AI-based Clinical Trial Solution Providers Market: Clinical Trial Phase Estimates & Trend Analysis
                   4.1 Definitions & Scope
                   4.2 Global AI-based Clinical Trial Solution Providers Market: Clinical Trial Phase Market Share Analysis, 2021 and 2030
                   4.3 Phase-I
                       4.3.1 Phase-I analysis Market Estimates and Forecasts, 2017 - 2030
                       4.3.2 Phase-II
                           4.3.2.1 Phase-II analysis Market Estimates and Forecasts, 2017 - 2030
                       4.3.3 Phase-III
                           4.3.3.1 Phase-III analysis Market Estimates and Forecasts, 2017 - 2030
Chapter 5 AI-based Clinical Trial Solution Providers Market: Therapeutic Application Estimates & Trend Analysis
                   5.1 Definitions & Scope
                   5.2 Global AI-based Clinical Trial Solution Providers Market: Therapeutic Application Market Share Analysis, 2021 and 2030
                   5.3 Oncology
                       5.3.1 Oncology analysis Market Estimates and Forecasts, 2017 - 2030
                   5.4 Cardiovascular Diseases
                       5.4.1 Cardiovascular Diseases analysis Market Estimates and Forecasts, 2017 - 2030
                   5.5 Neurological Diseases or Conditions
                       5.5.1 Neurological Diseases or Conditions analysis Market Estimates and Forecasts, 2017 - 2030
                   5.6 Metabolic Diseases
                       5.6.1 Metabolic Diseases analysis Market Estimates and Forecasts, 2017 - 2030
                   5.7 Infectious Diseases
                       5.7.1 Infectious Diseases analysis Market Estimates and Forecasts, 2017 - 2030
                   5.8 Others
                       5.8.1 Others analysis Market Estimates and Forecasts, 2017 - 2030
Chapter 6 AI-based Clinical Trial Solution Providers Market: End-Use Estimates & Trend Analysis
                   6.1 Definitions & Scope
                   6.2 Global AI-based Clinical Trial Solution Providers Market: End-Use Market Share Analysis, 2020 and 2030
                   6.3 Pharmaceutical Companies
                       6.3.1 Pharmaceutical Companies analysis Market Estimates and Forecasts, 2017 - 2030
                   6.4 Academia
                       6.4.1 Academia analysis Market Estimates and Forecasts, 2017 - 2030
                   6.5 Others
                       6.5.1 Others analysis Market Estimates and Forecasts, 2017 - 2030
Chapter 7 AI-based Clinical Trial Solution Providers Market: Regional Estimates & Trend Analysis, By Clinical Trial Phase, Therapeutic Application & End-Use
                   7.1 Global AI-based Clinical Trial Solution Providers Market: Regional Movement Analysis
                   7.2 North America
                       7.2.1 North America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.2.2 U.S.
                           7.2.2.1 U.S. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.2.3 Canada
                           7.2.3.1 Canada AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                   7.3 Europe
                       7.3.1 Europe AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.3.2 U.K.
                           7.3.2.1 U.K. AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.3.3 Germany
                           7.3.3.1 Germany AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.3.4 Spain
                           7.3.4.1 Spain AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.3.5 France
                           7.3.5.1 France AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.3.6 Italy
                           7.3.6.1 Italy AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.3.7 Russia
                           7.3.7.1 Russia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                   7.4 Asia Pacific
                       7.4.1 Asia Pacific AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.4.2 China
                           7.4.2.1 China AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.4.3 Japan
                           7.4.3.1 Japan AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.4.4 India
                           7.4.4.1 India AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.4.5 South Korea
                           7.4.5.1 South Korea AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.4.6 Australia
                           7.4.6.1 Australia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                   7.5 Latin America
                       7.5.1 Latin America AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.5.2 Brazil
                           7.5.2.1 Brazil AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.5.3 Mexico
                           7.5.3.1 Mexico AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.5.4 Argentina
                           7.5.4.1 Argentina AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                   7.6 MEA
                       7.6.1 MEA AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.6.2 South Africa
                           7.6.2.1 South Africa AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.6.3 Saudi Arabia
                           7.6.3.1 Saudi Arabia AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
                       7.6.4 UAE
                           7.6.4.1 UAE AI-based Clinical Trial Solution Providers Market Estimates And Forecasts By Clinical Trial Phase, Therapeutic Application, and End-Use 2017 - 2030
Chapter 8 Company Profiles
                   8.1 Unlearn.AI, Inc.
                       8.1.1 Company Overview
                       8.1.2 Financial Performance
                       8.1.3 Product Benchmarking
                       8.1.4 Strategic Initiatives
                   8.2 Saama Technologies
                       8.2.1 Company Overview
                       8.2.2 Financial Performance
                       8.2.3 Product Benchmarking
                       8.2.4 Strategic Initiatives
                   8.3 Antidote Technologies, Inc.
                       8.3.1 Company Overview
                       8.3.2 Financial Performance
                       8.3.3 Product Benchmarking
                       8.3.4 Strategic Initiatives
                   8.4 Exscientia
                       8.4.1 Company Overview
                       8.4.2 Financial Performance
                       8.4.3 Product Benchmarking
                       8.4.4 Strategic Initiatives
                   8.5 Google Inc. (Verily)
                       8.5.1 Company Overview
                       8.5.2 Financial Performance
                       8.5.3 Product Benchmarking
                       8.5.4 Strategic Initiatives
                   8.6 IBM Watson
                       8.6.1 Company Overview
                       8.6.2 Financial Performance
                       8.6.3 Product Benchmarking
                       8.6.4 Strategic Initiatives
                   8.7 GNS Healthcare
                       8.7.1 Company Overview
                       8.7.2 Financial Performance
                       8.7.3 Product Benchmarking
                       8.7.4 Strategic Initiatives
                   8.8 BioSymetrics
                       8.8.1 Company Overview
                       8.8.2 Financial Performance
                       8.8.3 Product Benchmarking
                       8.8.4 Strategic Initiatives
                   8.9 Euretos
                       8.9.1 Company Overview
                       8.9.2 Financial Performance
                       8.9.3 Product Benchmarking
                       8.9.4 Strategic Initiatives
                   8.10 Koneksa Health
                       8.10.1 Company Overview
                       8.10.2 Financial Performance
                       8.10.3 Product Benchmarking
                       8.10.4 Strategic Initiatives
                   8.11 Trials.Ai
                       8.11.1 Company Overview
                       8.11.2 Financial Performance
                       8.11.3 Product Benchmarking
                       8.11.4 Strategic Initiatives
                   8.12 Ardigen
                       8.12.1 Company Overview
                       8.12.2 Financial Performance
                       8.12.3 Product Benchmarking
                       8.12.4 Strategic Initiatives
                   8.13 Pharmaseal
                       8.13.1 Company Overview
                       8.13.2 Financial Performance
                       8.13.3 Product Benchmarking
                       8.13.4 Strategic Initiatives
                   8.14 Halo Health Systems
                       8.14.1 Company Overview
                       8.14.2 Financial Performance
                       8.14.3 Product Benchmarking
                       8.14.4 Strategic Initiatives
                   8.15 DEEP LENS AI
                       8.15.1 Company Overview
                       8.15.2 Financial Performance
                       8.15.3 Product Benchmarking
                       8.15.4 Strategic Initiatives
                   8.16 CONSILX
                       8.16.1 Company Overview
                       8.16.2 Financial Performance
                       8.16.3 Product Benchmarking
                       8.16.4 Strategic Initiatives
                   8.17 AiCure, LLC
                       8.17.1 Company Overview
                       8.17.2 Financial Performance
                       8.17.3 Product Benchmarking
                       8.17.4 Strategic Initiatives
                   8.18 BioAge Labs, Inc.
                       8.18.1 Company Overview
                       8.18.2 Financial Performance
                       8.18.3 Product Benchmarking
                       8.18.4 Strategic Initiatives
                   8.19 Symphony AI
                       8.19.1 Company Overview
                       8.19.2 Financial Performance
                       8.19.3 Product Benchmarking
                       8.19.4 Strategic Initiatives
                   8.20 Median Technologies
                       8.20.1 Company Overview
                       8.20.2 Financial Performance
                       8.20.3 Product Benchmarking
                       8.20.4 Strategic Initiatives
                   8.21 Intelligencia
                       8.21.1 Company Overview
                       8.21.2 Financial Performance
                       8.21.3 Product Benchmarking
                       8.21.4 Strategic Initiatives
                   8.22 Mendel.ai
                       8.22.1 Company Overview
                       8.22.2 Financial Performance
                       8.22.3 Product Benchmarking
                       8.22.4 Strategic Initiatives
                   8.23 Innoplexus
                       8.23.1 Company Overview
                       8.23.2 Financial Performance
                       8.23.3 Product Benchmarking
                       8.23.4 Strategic Initiatives
                   8.24 Deep 6 AI
                       8.24.1 Company Overview
                       8.24.2 Financial Performance
                       8.24.3 Product Benchmarking
                       8.24.4 Strategic Initiatives
                   8.25 Phesi
                       8.25.1 Company Overview
                       8.25.2 Financial Performance
                       8.25.3 Product Benchmarking
                       8.25.4 Strategic Initiatives

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert